Original Applications

GUIDANCE FOR SPONSORS, INDUSTRY, RESEARCHERS,
INVESTIGATORS, AND FOOD AND
DRUG ADMINISTRATION STAFF
Certifications To Accompany Drug, Biological Product, and Device
Applications/Submissions: Compliance with Section 402(j) of
The Public Health Service Act,
Added By Title VIII of The Food and Drug Administration
Amendments Act of 2007

Additional copies are available from:
Office of Policy, Office of the Commissioner
Food and Drug Administration
White Oak Building 1, Room 4305
10903 New Hampshire Avenue
Silver Spring, MD, 20993
301-796-4830.
http://www.fda.gov/oc/initiatives/advance/fdaaa.html

U.S. Department of Health and Human Services
Food and Drug Administration
Office of Policy, Office of the Commissioner
January 2009

This document was revised on March 5, 2009 to correct an error on page 9.

Contains Nonbinding Recommendations

Guidance for Sponsors, Industry, Researchers,
Investigators, and Food and Drug Administration Staff

Certifications To Accompany Drug, Biological Product, and Device
Applications/Submissions: Compliance with Section 402(j) of
The Public Health Service Act,
Added By Title VIII of The Food and Drug
Administration Amendments Act of 2007

This guidance document represents the Food and Drug Administration’s current thinking on this
topic. It does not create or confer any rights for or on any person and does not operate to bind
FDA or the public. You may use an alternative approach if the approach satisfies the
requirements of the applicable statutes and regulations. If you want to discuss an alternative
approach, please contact the appropriate FDA staff.

I.

Introduction

This guidance describes the Food and Drug Administration’s (FDA or Agency) current thinking
regarding the types of applications and submissions that sponsors, industry, researchers, and
investigators submit to the Agency with accompanying certifications under section 402(j)(5)(B)
of the Public Health Service Act (PHS Act), 42 U.S.C. § 282(j)(5)(B). New section 402(j) of the
PHS Act was added by Title VIII of the Food and Drug Administration Amendments Act of
2007 (FDAAA) (Public Law 110-85).

1

Contains Nonbinding Recommendations

FDA’s guidance documents, including this guidance, do not establish legally enforceable rights
or responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and
should be viewed only as recommendations, unless specific regulatory or statutory requirements
are cited. The use of the word should in Agency guidances means that something is suggested or
recommended, but not required.

II.

Background

Title VIII of FDAAA, Public Law 110-85, amended the PHS Act by adding new section 402(j),
42 U.S.C. § 282(j). The new provisions require that additional information be submitted to the
clinical trials data bank (www.ClinicalTrials.gov) previously established by the National
Institutes of Health (NIH)/National Library of Medicine (NLM), including expanded information
on clinical trials and information regarding the results of clinical trials.

One new provision, 42 U.S.C. § 282(j)(5)(B), section 402(j)(5)(B) of the PHS Act, requires that
a certification accompany certain human drug, biological product, and device applications and
submissions to FDA. The new provision reads as follows:

(B) CERTIFICATION TO ACCOMPANY DRUG, BIOLOGICAL
PRODUCT, AND DEVICE SUBMISSIONS.—At the time of submission

2

Contains Nonbinding Recommendations

of an application under section 505 of the Federal Food, Drug, and Cosmetic Act,
section 515 of such Act, section 520(m) of such Act, or section 351 of this Act,
or submission of a report under section 510(k) of such Act, such application or
submission shall be accompanied by a certification that all applicable
requirements of this subsection have been met. Where available, such certification
shall include the appropriate National Clinical Trial control numbers.

The certification requirement went into effect on December 26, 2007. To assist sponsors,
industry, researchers, and investigators in complying with the requirement, FDA created a
certification form to be used to satisfy the certification requirement. This form is FDA Form
3674, OMB Control No. 0910-0616. The form can be obtained at
www.fda.gov/opacom/morechoices/fdaforms/default.html.

III. Purpose and Agency Recommendations

FDA has received numerous inquiries asking whether various kinds of information and
documents that sponsors, industry, researchers, and investigators submit to the Agency must be
accompanied by the certification. FDA also has had experience with the submission of
certifications since the form was implemented. This guidance provides FDA’s current thinking,
for purposes of implementing Title VIII of FDAAA,1 regarding specific types of applications and

1

In particular, the Agency’s discussion of “applications” and “submissions” in this guidance is not necessarily
applicable to any other provision of law.

3

Contains Nonbinding Recommendations

submissions submitted to FDA under section 505, 515, 520(m), or 510(k) of the Federal Food,
Drug, and Cosmetic Act (the Act), or under section 351 of the PHS Act, and accompanying
certifications described in section 402(j)(5)(B), 42 U.S.C § 282(j)(5)(B).

The purpose of Title VIII is to provide a means for ensuring that the public has access to
information about certain clinical trials. Specifically, Title VIII is intended to provide a
mechanism for the public to learn about certain clinical trials that are being conducted, as well as
the results of those trials. In determining its current thinking on specific applications and
submissions submitted under the statutory sections cited above and submission of accompanying
certifications, FDA has focused on the role the certification plays in helping achieve the purposes
of Title VIII of FDAAA.

One purpose of the certification is to require the submitter to confirm that it has complied with
all applicable requirements of Title VIII, including the requirement to register applicable clinical
trials.2 Failure to submit a certification, knowingly submitting a false certification, failure to
submit required clinical trial information, and submission of clinical trial information that is false
or misleading are all newly added prohibited acts under section 301(jj) of the Act (21 U.S.C. §
331(jj)). Requiring a certification to accompany certain applications and submissions submitted
to FDA is, therefore, one way of encouraging compliance with the provisions of the law.

2

“Applicable clinical trial” is defined at section 402(j)(1)(A)(i) of the PHS Act (42 U.S.C. § 282(j)(1)(A)(i)). For
additional information, visit http://prsinfo.clinicaltrials.gov.

4

Contains Nonbinding Recommendations

The certification also facilitates FDA’s exercise of its responsibilities under the new law. For
example, as stated previously, FDAAA created four new prohibited acts relating to compliance
with the requirements of Title VIII, including compliance with the requirement to submit a
certification. The certification requirement is critical to the Agency’s ability to determine
whether the law has been complied with and whether an enforcement action is appropriate. In
addition, section 402(j)(3)(F) of the PHS Act (42 U.S.C. § 282(j)(3)(F)) requires FDA to notify
the Director of NIH of certain actions taken on applications and reports that were accompanied
by a certification. That notification alerts NIH to the fact that the responsible party must submit
the results of the trials within a certain period of time, thereby enabling NIH to exercise its
responsibilities under Title VIII. The information provided in the certification form also will
help FDA assist NIH in “linking” information posted on FDA’s website regarding certain FDA
regulatory actions to specific applicable clinical trials included in the registry and results
databases. This linking, using the information in the certification form, particularly the NCT
(National Clinical Trial) number(s) required in the form, eventually will allow FDA to help the
public more easily correlate various reports, medical reviews, advisories, health alerts, advisory
committee actions, and other materials with specific applicable clinical trials registered with
ClinicalTrials.gov and identified by the NCT number.

New drug applications (NDAs), supplemental NDAs, biologics license applications (BLAs),
supplemental BLAs, abbreviated new drug applications (ANDAs), premarket approval
applications (PMAs), PMA “panel track” supplements, humanitarian device exemptions (HDEs),
and resubmissions of these, are all “applications” under their respective sections of the Act or the

5

Contains Nonbinding Recommendations

PHS Act. Similarly, 510(k)s are “submissions of a report” under that section of the Act. Thus,
all of these specified applications and submissions fall within the plain language of the statutory
provision. Additionally, they all represent the initiation of the regulatory review process
through which clinical investigations supporting approval of a previously unapproved medical
product are submitted to FDA for marketing approval of that product. Because amendments to
pending applications, pending supplemental applications, or pending submissions of 510(k)s are
not independently “applications” or “submissions of a report under 510(k),” such amendments
need not be accompanied by a certification.

We believe that the statutory requirement to submit a certification also applies to investigational
new drug applications (INDs) and the submissions of new protocols to INDs. INDs are
authorized under § 505(i) of the Act (see also 21 C.F.R. § 312.3 (defining “IND” as “an
investigational new drug application”)). We also have concluded that a certification must
accompany the submission of a new clinical protocol to an IND as described in 21 CFR §
312.30(a). There are a number of different types of submissions to an IND that are referred to as
“amendments” under FDA’s regulations, but these types of submissions are varied as to their
purpose and the role they play in the regulatory process. One type of submission is that of a new
protocol submitted to a pending IND. A new clinical protocol that is submitted to a pending
IND, for a study not already included in an existing protocol, is the investigational stage analog
to an efficacy supplement to an NDA or BLA for a new indication not already covered by the
existing application. New protocols are referred to as amendments to INDs, and are submitted to
existing INDs, as a matter of regulatory process; FDA could have required that new protocols

6

Contains Nonbinding Recommendations

filed with the Agency be submitted to a new IND, but for administrative ease chose to have them
submitted to the existing IND. In contrast, other types of amendments to pending INDs are more
analogous to amendments to NDAs, BLAs, and PMAs; as such, consistent with our
interpretation of the statute with regard to amendments to NDAs, BLAs, and PMAs,
certifications need not be submitted with IND amendments other than submission of a new
protocol to an existing IND.

FDA intends to exercise enforcement discretion with regard to submission of certifications with
four categories of applications and submissions: 1) a supplement to an approved NDA, BLA, or
PMA other than an efficacy supplement (for NDAs and BLAs) or a panel track supplement (for
PMAs), 2) a supplement to an approved ANDA, 3) INDs that fall within the types of INDs
described in section 561 of the Act (21 U.S.C. § 360bbb), and 4) submission of a 510(k) if that
submission does not refer to, relate to, or include information on or from a clinical trial. FDA
believes that, in contrast to the types of applications and submissions discussed above, the
majority of supplements to approved NDAs, BLAs, and PMAs do not refer to, relate to, or
include information on or from a clinical trial. Furthermore, even to the extent that, for example,
a labeling supplement to an approved NDA may refer to, relate to, or include information on or
from one or more clinical trials, those clinical trials in all likelihood were conducted under an
IND, and therefore the sponsor would already have submitted a certification regarding those
trials during the investigational phase. It would be repetitive and would serve little or no purpose
to have a sponsor repeatedly certify to having complied with the requirements of Title VIII of
FDAAA with regard to the same clinical trial.

7

Contains Nonbinding Recommendations

With regard to supplements to approved ANDAs, even when such supplements are intended to
add an additional indication (such as when existing patents or exclusivities have expired), such
supplements would not ordinarily refer to, relate to, or include information on or from any
clinical trial other than those which were referenced or referred to in the original ANDA
submission. Thus, as with non-efficacy supplements to approved NDAs and BLAs, and nonpanel track supplements to approved PMAs, certification with a supplemental ANDA would be
repetitive, and would serve little or no purpose with regard to ensuring that the requirements of
Title VIII had been met.

With regard to INDs that fall within the types of INDs described in section 561 of the Act (21
U.S.C. § 360bbb), none of the clinical trials conducted under such INDs will meet the definition
of applicable drug clinical trial in section 402(j)(1)(A)(iii) of the PHS Act (42 U.S.C.
§ 282(j)(1)(A)(iii)), and thus none of those trials will be subject to the registration and reporting
requirements as set forth in Title VIII of FDAAA. One of the criteria for being an applicable
drug clinical trial is that the trial at issue is a “controlled clinical investigation.” Trials conducted
under INDs that fall within the types of INDs described in section 561 of the Act are not
controlled. Because none of the clinical trials conducted under an IND of the type described in
section 561 of the Act would be subject to the requirements of Title VIII of FDAAA,
certification with regard to such clinical trials when submitting an IND for such a clinical trial
would serve little or no purpose with regard to ensuring that the requirements of Title VIII had
been met.

8

Contains Nonbinding Recommendations

Finally, with regard to 510(k)s, the majority of 510(k) submissions do not refer to, relate to, or
include information on or from a clinical trial. Accordingly, FDA believes that certification with
regard to 510(k) submissions that do not refer to, relate to, or include information on or from a
clinical trial would serve little or no purpose with regard to ensuring that the requirements of
Title VIII had been met.

Because FDA believes that the statutory purposes of Title VIII would not be furthered by the
submission of certifications with these four categories of applications and submissions, the
Agency intends to exercise enforcement discretion regarding certification with these applications
and submissions.

Based on these considerations and as described above, FDA recommends that a certification
accompany the following types of applications and submissions:

Applications/Submissions (including Resubmissions)
IND
New Clinical Protocol Submitted to an IND
NDA
Efficacy Supplement to an Approved NDA
BLA
Efficacy Supplement to an Approved BLA

9

Contains Nonbinding Recommendations

ANDA
PMA
PMA Panel Track Supplement
HDE
510(k) that refers to, relates to, or includes information on a clinical trial

IV. Paperwork Reduction Act of 1995

This guidance refers to previously approved collections of information. These collections of
information are subject to review by the Office of Management and Budget (OMB) under the
Paperwork Reduction Act of 1995 (44 U.S.C. §§ 3501-3520). The collections of information
have been approved under OMB Control No. 0910-0616.

10